Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

June 1, 2026

Conditions

Brain Glioma

Interventions

DRUG

Bevacizumab

Patients were enrolled and given bevacizumab on days 1 and 15, administered by intravenous infusion at 5 mg/kg.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Zhengzhou University

OTHER